BRPI0411219A - seqüências de hbv e hcv conservadas úteis para silenciamento de gene - Google Patents
seqüências de hbv e hcv conservadas úteis para silenciamento de geneInfo
- Publication number
- BRPI0411219A BRPI0411219A BRPI0411219-9A BRPI0411219A BRPI0411219A BR PI0411219 A BRPI0411219 A BR PI0411219A BR PI0411219 A BRPI0411219 A BR PI0411219A BR PI0411219 A BRPI0411219 A BR PI0411219A
- Authority
- BR
- Brazil
- Prior art keywords
- hbv
- gene silencing
- useful
- hcv
- sequences useful
- Prior art date
Links
- 230000030279 gene silencing Effects 0.000 title abstract 3
- 238000012226 gene silencing method Methods 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 abstract 3
- 108091035707 Consensus sequence Proteins 0.000 abstract 1
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47807603P | 2003-06-12 | 2003-06-12 | |
| PCT/US2004/019229 WO2005014806A2 (en) | 2003-06-12 | 2004-06-10 | Conserved hbv and hcv sequences useful for gene silencing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0411219A true BRPI0411219A (pt) | 2006-07-18 |
Family
ID=34135047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0411219-9A BRPI0411219A (pt) | 2003-06-12 | 2004-06-10 | seqüências de hbv e hcv conservadas úteis para silenciamento de gene |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8350021B2 (enExample) |
| EP (4) | EP3470518A1 (enExample) |
| JP (2) | JP4980716B2 (enExample) |
| CN (1) | CN1836042A (enExample) |
| AU (1) | AU2004263832B2 (enExample) |
| BR (1) | BRPI0411219A (enExample) |
| CA (2) | CA3040025C (enExample) |
| DK (1) | DK2270162T3 (enExample) |
| HU (1) | HUE042261T2 (enExample) |
| IL (1) | IL172268A0 (enExample) |
| SG (1) | SG173218A1 (enExample) |
| SI (1) | SI2270162T1 (enExample) |
| WO (1) | WO2005014806A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8575327B2 (en) | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
| DK2270162T3 (en) * | 2003-06-12 | 2019-01-21 | Alnylam Pharmaceuticals Inc | PRESERVED HBV AND HCV SEQUENCES USED FOR GEN-SILENCING |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| US8084599B2 (en) | 2004-03-15 | 2011-12-27 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| EP2270161A3 (en) | 2004-08-23 | 2011-02-02 | Alnylam Pharmaceuticals, Inc. | Multiple RNA polymerase III promoter expression constructs |
| EP1797185B1 (en) | 2004-09-24 | 2011-04-13 | Alnylam Pharmaceuticals, Inc. | Targeting opposite strand replication intermediates of single-stranded viruses by rnai |
| EP2316942B1 (en) * | 2004-12-22 | 2021-04-21 | Alnylam Pharmaceuticals, Inc. | Conserved hbv and hcv sequences useful for gene silencing |
| WO2011103394A2 (en) * | 2010-02-19 | 2011-08-25 | Agave Pharma Inc. | Methods for gene inhibition |
| AU2011223820B2 (en) | 2010-03-01 | 2016-01-14 | The Children's Hospital Of Philadelphia | Nucleic acids for targeting multiple regions of the HCV genome |
| JP2013537423A (ja) | 2010-08-17 | 2013-10-03 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| MX347253B (es) | 2011-04-21 | 2017-04-20 | Ionis Pharmaceuticals Inc | Modulación de la expresión del virus de hepatitis b (vhb). |
| NZ705730A (en) | 2012-08-30 | 2016-06-24 | Replicor Inc | Methods for the treatment of hepatitis b and hepatitis d infections |
| JP6566941B2 (ja) | 2013-06-28 | 2019-08-28 | ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ | 多発性硬化症のための樹状細胞ａｓｇｐｒ標的化免疫治療薬 |
| CN105899658B (zh) | 2013-12-12 | 2020-02-18 | 布罗德研究所有限公司 | 针对hbv和病毒性疾病以及障碍的crispr-cas系统和组合物的递送、用途和治疗应用 |
| JOP20200092A1 (ar) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
| AU2016257150B2 (en) * | 2015-05-06 | 2022-03-31 | Benitec IP Holdings Inc. | Reagents for treatment of hepatitis B virus (HBV) infection and use thereof |
| US20170137821A1 (en) | 2015-07-17 | 2017-05-18 | Arcturus Therapeutics, Inc. | Molecules and agents for treating hepatitis b virus |
| WO2017015175A1 (en) | 2015-07-17 | 2017-01-26 | Arcturus Therapeutics, Inc. | Compositions and agents against hepatitis b virus and uses thereof |
| TWI840950B (zh) | 2016-03-14 | 2024-05-01 | 瑞士商赫孚孟拉羅股份公司 | 用於降低pd-l1表現之寡核苷酸 |
| EP3472346B1 (en) | 2016-06-17 | 2023-01-18 | F. Hoffmann-La Roche AG | Papd5 and papd7 inhibitors for treating a hepatitis b infection |
| WO2018102397A1 (en) | 2016-11-29 | 2018-06-07 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
| WO2019051812A1 (zh) * | 2017-09-15 | 2019-03-21 | 深圳华大智造科技有限公司 | 确定预定染色体保守区域的方法、确定样本基因组中是否存在拷贝数变异的方法、系统和计算机可读介质 |
| TW202424191A (zh) | 2017-10-16 | 2024-06-16 | 瑞士商赫孚孟拉羅股份公司 | 用於降低PAPD5及PAPD7 mRNA以治療B型肝炎感染之核酸分子 |
| SG11202009680XA (en) | 2018-04-05 | 2020-10-29 | Hoffmann La Roche | Use of fubp1 inhibitors for treating hepatitis b virus infection |
| PE20220013A1 (es) | 2018-07-03 | 2022-01-11 | Hoffmann La Roche | Oligonucleotidos para modular la expresion de tau |
| BR112021000538A2 (pt) | 2018-07-13 | 2021-04-06 | F. Hoffmann-La Roche Ag | Oligonucleotídeos para modular a expressão de rtel1 |
| MX2021001056A (es) | 2018-08-13 | 2021-04-12 | Alnylam Pharmaceuticals Inc | Composiciones de agente de acido ribonucleico bicatenario (arnbc) de virus de la hepatitis b (vhb) y metodos de uso de las mismas. |
| CN114829601A (zh) | 2019-12-19 | 2022-07-29 | 豪夫迈·罗氏有限公司 | Sbds抑制剂用于治疗乙型肝炎病毒感染的用途 |
| CN114867856A (zh) | 2019-12-19 | 2022-08-05 | 豪夫迈·罗氏有限公司 | Saraf抑制剂用于治疗乙型肝炎病毒感染的用途 |
| JP7634542B2 (ja) | 2019-12-19 | 2025-02-21 | エフ． ホフマン－ラ ロシュ アーゲー | Ｂ型肝炎ウイルス感染症を処置するためのｓｅｐｔ９阻害剤の使用 |
| JP2023506540A (ja) | 2019-12-19 | 2023-02-16 | エフ． ホフマン－ラ ロシュ エージー． | Ｂ型肝炎ウイルス感染を処置するためのｓｃａｍｐ３阻害剤の使用 |
| JP7653997B2 (ja) | 2019-12-19 | 2025-03-31 | エフ． ホフマン－ラ ロシュ アーゲー | Ｂ型肝炎ウイルス感染を処置するためのｃｏｐｓ３阻害剤の使用 |
| JP2023538630A (ja) | 2020-08-21 | 2023-09-08 | エフ． ホフマン－ラ ロシュ アーゲー | Ｂ型肝炎ウイルス感染症を処置するためのａ１ｃｆ阻害剤の使用 |
| TW202246500A (zh) | 2021-02-02 | 2022-12-01 | 瑞士商赫孚孟拉羅股份公司 | 用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸 |
| WO2023111210A1 (en) | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Combination of oligonucleotides for modulating rtel1 and fubp1 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5643771A (en) | 1980-05-19 | 1997-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Non-reverting live bacterial vaccines |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| DE68927996T2 (de) | 1988-02-05 | 1997-12-04 | Hughes Howard Med Inst | Modifizierte hepatozyten und deren anwendung |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| WO1991019809A1 (en) | 1990-06-18 | 1991-12-26 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Eukaryotic expression vector system |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| US20030206887A1 (en) * | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| JPH10503364A (ja) * | 1994-05-10 | 1998-03-31 | ザ ジェネラル ホスピタル コーポレーション | Ｃ型肝炎ウイルスのアンチセンス阻害 |
| JPH07303485A (ja) * | 1994-05-13 | 1995-11-21 | Tonen Corp | Ｈｃｖアンチセンスｒｎａ、それを含む発現ベクター、及び該ｒｎａ又は発現ベクターを含むｈｃｖ関連疾患治療剤 |
| US5646262A (en) * | 1994-07-28 | 1997-07-08 | Georgetown University | Antisense oligonucleotides against hepatitis B viral replication |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US5571026A (en) * | 1994-12-09 | 1996-11-05 | Kcs Industries, Inc. | Flat mount electrode socket |
| US6057153A (en) * | 1995-01-13 | 2000-05-02 | Yale University | Stabilized external guide sequences |
| US5877159A (en) | 1995-05-03 | 1999-03-02 | University Of Maryland At Baltimore | Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same |
| US5932241A (en) | 1995-06-07 | 1999-08-03 | Valentis, Incorporated | Cationic lipid DNA complexes for gene targeting |
| US5824538A (en) | 1995-09-06 | 1998-10-20 | The United States Of America As Represented By The Secretary Of The Army | Shigella vector for delivering DNA to a mammalian cell |
| US5843770A (en) * | 1996-03-11 | 1998-12-01 | The Immune Response Corporation | Antisense constructs directed against viral post-transcriptional regulatory sequences |
| US5877162A (en) * | 1996-03-14 | 1999-03-02 | Innovir Laboratories, Inc. | Short external guide sequences |
| US6610478B1 (en) * | 1996-08-16 | 2003-08-26 | Yale University | Phenotypic conversion of cells mediated by external guide sequences |
| US5981274A (en) * | 1996-09-18 | 1999-11-09 | Tyrrell; D. Lorne J. | Recombinant hepatitis virus vectors |
| US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
| DE19725803C1 (de) | 1997-06-18 | 1999-02-11 | Deutsches Krebsforsch | HBV-gerichtete Antisense-Nukleinsäuren |
| WO1999021591A1 (en) | 1997-10-28 | 1999-05-06 | American Home Products Corporation | Compositions and methods for delivery of genetic material |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| DE69902086T2 (de) * | 1998-01-27 | 2003-03-13 | Cytocell Ltd., Banbury | Verfahren zum nachweis von nukleinsäure-zielsequenzen mittels in vitro transkription von einem rna-promoter |
| KR20010041902A (ko) | 1998-03-16 | 2001-05-25 | 데이비드 엠 모이어 | 포유류의 피부 내의 셀룰라이트를 감소시키는 방법 |
| BR0009884A (pt) | 1999-04-21 | 2002-01-08 | American Home Prod | Processos e composições para a inibição da função das sequências de polinucleotìdeos |
| US6533250B2 (en) | 1999-10-15 | 2003-03-18 | W. Eugene Arthur | Energy dissipating system for a concrete roadway barrier |
| WO2003070918A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
| PT1309726E (pt) * | 2000-03-30 | 2010-03-08 | Whitehead Biomedical Inst | Mediadores de interferência por rna específicos de sequência de rna |
| US7439016B1 (en) * | 2000-06-15 | 2008-10-21 | Digene Corporation | Detection of nucleic acids by type-specific hybrid capture method |
| US6680059B2 (en) * | 2000-08-29 | 2004-01-20 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
| US6443403B1 (en) | 2000-09-11 | 2002-09-03 | Panduit Corp. | Cable routing clamp and method of application |
| JP2002335968A (ja) | 2001-05-16 | 2002-11-26 | Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho | 新規転写因子、その遺伝子及びその結合ｄｎａ配列 |
| IL159756A0 (en) | 2001-07-12 | 2004-06-20 | Univ Massachusetts | IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING |
| AU2002321859A1 (en) | 2001-08-03 | 2003-02-24 | Michael Van Der Sleesen | Protective garment |
| US7103761B2 (en) | 2001-08-07 | 2006-09-05 | Hewlett-Packard Development Company, Lp. | Server system with multiple management user interfaces |
| US6673661B1 (en) | 2002-12-20 | 2004-01-06 | Taiwan Semiconductor Manufacturing Co., Ltd. | Self-aligned method for forming dual gate thin film transistor (TFT) device |
| JP4545091B2 (ja) | 2003-01-24 | 2010-09-15 | 財団法人 東京都医学研究機構 | Ｃ型肝炎ウイルスの働きを阻害するオリゴリボヌクレオチドまたはペプチド核酸 |
| CN1257284C (zh) | 2003-03-05 | 2006-05-24 | 北京博奥生物芯片有限责任公司 | 一种体外阻断乙肝病毒表达的方法 |
| DK2270162T3 (en) | 2003-06-12 | 2019-01-21 | Alnylam Pharmaceuticals Inc | PRESERVED HBV AND HCV SEQUENCES USED FOR GEN-SILENCING |
| EP2270161A3 (en) * | 2004-08-23 | 2011-02-02 | Alnylam Pharmaceuticals, Inc. | Multiple RNA polymerase III promoter expression constructs |
| JP2015086965A (ja) | 2013-10-31 | 2015-05-07 | 株式会社エクセディ | フライホイール組立体 |
-
2004
- 2004-06-10 DK DK10180048.0T patent/DK2270162T3/en active
- 2004-06-10 SI SI200432456T patent/SI2270162T1/sl unknown
- 2004-06-10 EP EP18192425.9A patent/EP3470518A1/en active Pending
- 2004-06-10 JP JP2006533810A patent/JP4980716B2/ja not_active Expired - Fee Related
- 2004-06-10 BR BRPI0411219-9A patent/BRPI0411219A/pt not_active Application Discontinuation
- 2004-06-10 CA CA3040025A patent/CA3040025C/en not_active Expired - Lifetime
- 2004-06-10 EP EP10180047A patent/EP2284268A3/en not_active Withdrawn
- 2004-06-10 EP EP04776661A patent/EP1631670B1/en not_active Expired - Lifetime
- 2004-06-10 US US10/560,377 patent/US8350021B2/en not_active Expired - Fee Related
- 2004-06-10 CN CNA2004800228949A patent/CN1836042A/zh active Pending
- 2004-06-10 AU AU2004263832A patent/AU2004263832B2/en not_active Expired
- 2004-06-10 HU HUE10180048A patent/HUE042261T2/hu unknown
- 2004-06-10 CA CA2528510A patent/CA2528510C/en not_active Expired - Lifetime
- 2004-06-10 EP EP10180048.0A patent/EP2270162B1/en not_active Expired - Lifetime
- 2004-06-10 WO PCT/US2004/019229 patent/WO2005014806A2/en not_active Ceased
- 2004-06-10 SG SG2007044373A patent/SG173218A1/en unknown
-
2005
- 2005-11-30 IL IL172268A patent/IL172268A0/en unknown
-
2011
- 2011-07-04 JP JP2011148461A patent/JP5593279B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DK2270162T3 (en) | 2019-01-21 |
| EP1631670B1 (en) | 2012-08-08 |
| JP4980716B2 (ja) | 2012-07-18 |
| CA3040025C (en) | 2023-01-10 |
| CA2528510A1 (en) | 2005-02-17 |
| AU2004263832A1 (en) | 2005-02-17 |
| JP5593279B2 (ja) | 2014-09-17 |
| EP2270162A3 (en) | 2012-05-30 |
| EP2284268A2 (en) | 2011-02-16 |
| WO2005014806A2 (en) | 2005-02-17 |
| EP2270162A2 (en) | 2011-01-05 |
| EP3470518A1 (en) | 2019-04-17 |
| JP2011224013A (ja) | 2011-11-10 |
| CN1836042A (zh) | 2006-09-20 |
| WO2005014806A3 (en) | 2005-12-01 |
| JP2007503474A (ja) | 2007-02-22 |
| CA3040025A1 (en) | 2005-02-17 |
| US8350021B2 (en) | 2013-01-08 |
| EP2270162B1 (en) | 2018-10-03 |
| CA2528510C (en) | 2019-06-04 |
| EP2284268A3 (en) | 2012-05-30 |
| SI2270162T1 (sl) | 2019-03-29 |
| IL172268A0 (en) | 2006-04-10 |
| HUE042261T2 (hu) | 2019-06-28 |
| SG173218A1 (en) | 2011-08-29 |
| EP1631670A2 (en) | 2006-03-08 |
| AU2004263832B2 (en) | 2010-07-01 |
| US20080070854A1 (en) | 2008-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0411219A (pt) | seqüências de hbv e hcv conservadas úteis para silenciamento de gene | |
| BR0111827A (pt) | Vìrus de rna isolado, recombinantemente gerado, não segmentado, de sentido negativo, de filamento único do gênero morbillivìrus, composição imunogênica, método para imunizar um indivìduo para induzir proteção contra o dito vìrus, método para reduzir a repressão causada por uma proteìna v do gênero morbillivìrus, sequência de nucleotìdeos isolada, composição, e, método para produzir um morbillivìrus infeccioso | |
| BR0111732A (pt) | Prodrogas de 2-deóxi-beta-l-nucleosìdeos | |
| DE60319820D1 (de) | Pyrazoloä1,5-aüpyrimidin-verbindungen als antivirale agentien | |
| MY176918A (en) | N- [ (2 ' r) -2' -deoxy-2' -fluoro-2' -methyl-p-phenyl-5' -uridylyl] - l-alanine 1-methylethyl ester and process for its production | |
| BR9712138A (pt) | Vìrus de rna isolado, vacina, processo para imunizr um indivìduo para induzir proteção contra um vìrus de rna não segmentado, sentido negativo, de filamento único, da ordem mononegavirales e para produzir vìrus de rna, molécula de ácido nucleico isolada e composição. | |
| DK1554301T3 (da) | Dengue-vaccine med en fælles udeladelse af 30 nukleotider i Dengue-typerne 1's og 2's3'UTR | |
| BR9813485A (pt) | Virús da sìndrome de emaciação ou enfraquecimento gradual multisistêmico pós-desmame de porcos. | |
| PT100472A (pt) | Sequencias genomicas do virus da hepatite c e composicoes farmaceuticas que as contem, para diagnostico e terapeutica da hepatite c | |
| BR112012024923A2 (pt) | "fosforamidatos de nucleosídeo, composição, comprimido, e seus usos" | |
| WO2006069064A3 (en) | Conserved hbv and hcv sequences useful for gene silencing | |
| EA201000085A1 (ru) | dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ | |
| WO2006121464A3 (en) | Compositions for treating respiratory viral infections and their use | |
| Tellier et al. | Amplification of the full-length hepatitis A virus genome by long reverse transcription-PCR and transcription of infectious RNA directly from the amplicon. | |
| BR0316291A (pt) | Vacina contra hcv, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina contra hcv | |
| BR9913333A (pt) | Inibição e tratamento do vìrus da hepatite b e flavivìrus com helioxatina e seus análogos | |
| Ma et al. | Analyses of nucleotide, codon and amino acids usages between peste des petits ruminants virus and rinderpest virus | |
| EP1556493A4 (en) | NEW COMPLETE GENETIC DNA OF THE JAPANESE CEPHALITIS VIRUS, INFECTIOUS JEV CDNA FROM AND THEIR USE | |
| Miller et al. | The nucleotide sequence of RNA-1 of Indian peanut clump furovius | |
| BRPI0607487A2 (pt) | virus rna deficientes em replicação como vacinas | |
| WO2004070002A3 (en) | Cell lines and host nucleic acid sequences related to infectious disease | |
| EA200401362A1 (ru) | Антивирусная терапия, основанная на противодействии рнк | |
| KUMAR | Clinical, diagnostic and therapeutic implications of coronavirus ORFab polyprotein associated Nsp16 protein-a bioinformatics approach | |
| BR0211178A (pt) | Cadeias nucleotìdicas quiméricas, proteìnas quiméricas, preparação farmacêutica, e, método diagnóstico | |
| DOP2024000204A (es) | Composiciones y métodos para la prevención y el tratamiento de la infección por el virus de la rabia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: A CLASSIFICACAO ANTERIOR ERA: C12N 15/11 Ipc: A61K 48/00 (2006.01), C12N 15/11 (2006.01), A61P 3 |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |